Need an investment idea? Check out S2O Stock Screener. It allows to generate a list of stocks of a particular interest in a matter of seconds!

Market Price

121.50 

-2.50 -2.0%

as of Oct 21 '20

52 Week Range:

73.54 128.55


Stock Analyzer Tutorials

S2O Stock Analyzer - General Info

General Info


type: video (mp4); length: 3:30

Demonstrates how to use Stock Analyzer, shows how to analyze a stock and explains in detail "General Info" section of the Stock Analyzer result page.

S2O Stock Analyzer - Financial Statements

Financial Statements


type: video (mp4); length: 5:10

Explains information presented in the Financial Statements section of the S2O Stock Analyzer: financial statements charts, absolute values and growth rates.

S2O Stock Analyzer - Growth Grade and Financial Ratios

Growth Grade and Financial Ratios


type: video (mp4); length: 5:09

Demonstrates how to use Growth Grade & Financial Ratios section; shows the difference between historical and year-over-year Growth Grade on the real life example.

S2O Stock Analyzer - Value Price

Value Price


type: video (mp4); length: 6:03

Demonstrates how to use Value Price (intrinsic value) and the Graham Number, MOS (margin of safety) and IRT - Investment Recovery Time; explains 3 different projection models used to compute value price - pessimistic, moderate and optimistic.

S2O Stock Analyzer - Price Charts

Price Charts


type: video (mp4); length: 8:34

Demonstrates basic rules of how to read a candlestick chart, long and short term moving averages, stochastic, MACD and relative strength (RS) charts. Explains how bull or bear market condition is computed.

General Info

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. The company was founded in 1992 and is headquartered in Boston, Massachusetts.

Financial Statements

The charts below show selected Annual and Quarterly Financial Data.

The purpose of these charts is to discover long and short term change dynamics. When numbers are growing year after year in the annual statements chart, the business become stronger and stronger and this is a good sign.

Quarterly Data Chart can be used to do a short term analysis. It makes sense to pay attention to the quarterly dynamics and do not wait for the next yearly statement. We should be alerted if we see that quarterly numbers are going down.

You can check "Annual Financial Statements" and "Quarterly Financial Statements" sections for exact numbers and growth rates.

Annual Statements

On a charts below the Line shows absolute values and the Bar chart shows Year-Over-Year Growth Rate for selected financial statement item. A consistent GROWTH is generally considered necessary to fund future growth from within a business.
NOTE: Growth Rate is not provided if either the latest period or the year-ago period contains a net loss. (source: WSJ Digest of Earnings)
TIP! move your mouse pointer over bar or a circle on any chart below to see details.

Financial Statements

Income Statement



 

Cash Flow Statement



 

Balance Sheet



 

Liquidity Ratios

Current Ratio


 

Current Ratio measures the ability to meet short term obligations. Generally accepted standard is 2 (current assets should be 2 times or 200% of current liabilities).

Quick Ratio


 

Measures immediate liquidity or the cash available to cover immediate liabilities. A safe margin would be at least 1 (100%).

Financial Leverage


 

Defined as total assets divided by total shareholders' equity. The higher the ratio, the more debt a company uses in its capital structure.

Profitability Ratios

ROA


 

Return on Assets (ROA) measures the income (profit) that is generated by the use of the assets of the business.

ROE


 

Return on Equity (ROE) is a measure of profitability that calculates how many dollars of profit a company generates with each dollar of shareholders equity. ROE is sometimes called "return on net worth."

ROIC


 

The Return on Invested Capital (ROIC) measure gives a sense of how well a company is using its money to generate returns. Some investors use this figure as a final evaluation to determine whether or not to invest in a company.

Annual Statements

Item Name Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Equity (BVPS) 3.87
4.70
5.69
10.12
11.96
15.69
36.57
37.96
40.23
41.03
46.85
growth rate 21.5% 21.1% 77.9% 18.2% 31.2% 133.1% 3.8% 6.0% 2.0% 14.2%
Earnings BIT 83.31
149.01
229.67
397.57
526.27
916.00
682.20
793.40
983.30
1,619.90
2,139.90
growth rate 78.9% 54.1% 73.1% 32.4% 74.1% -25.5% 16.3% 23.9% 64.7% 32.1%
Avg.PE 14.99
77.52
78.13
72.99
105.26
55.92
210.61
74.74
50.98
345.23
16.62
growth rate 417.1% 0.8% -6.6% 44.2% -46.9% 276.6% -64.5% -31.8% 577.2% -95.2%
ROA 46.71
10.79
14.57
12.71
8.53
17.47
1.67
3.02
3.30
0.56
15.28
growth rate -76.9% 35.0% -12.8% -32.9% 104.8% -90.4% 80.8% 9.3% -83.0% 2,628.6%
ROE 63.11
12.54
17.58
16.41
11.62
23.11
2.50
4.71
5.04
0.86
23.53
growth rate -80.1% 40.2% -6.7% -29.2% 98.9% -89.2% 88.4% 7.0% -82.9% 2,636.1%
ROIC 54.21
12.34
17.44
15.94
11.00
21.99
2.26
3.91
4.34
1.22
18.71
growth rate -77.2% 41.3% -8.6% -31.0% 99.9% -89.7% 73.0% 11.0% -71.9% 1,433.6%
Cur. Ratio 4.38
4.67
4.09
4.15
3.75
4.61
3.38
3.13
3.10
2.88
4.25
growth rate 6.6% -12.4% 1.5% -9.6% 22.9% -26.7% -7.4% -1.0% -7.1% 47.6%
Quick Ratio 3.40
3.83
3.41
3.57
3.33
3.95
2.67
2.36
2.31
2.12
3.34
growth rate 12.7% -11.0% 4.7% -6.7% 18.6% -32.4% -11.6% -2.1% -8.2% 57.6%
Leverage 1.14
1.18
1.23
1.33
1.39
1.27
1.59
1.52
1.53
1.52
1.56
growth rate 3.5% 4.2% 8.1% 4.5% -8.6% 25.2% -4.4% 0.7% -0.7% 2.6%
Balance Sheet Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Acct.Receivable 113.70
168.70
263.42
321.68
463.18
432.89
533.00
649.60
726.50
922.30
1,243.20
growth rate 48.4% 56.2% 22.1% 44.0% -6.5% 23.1% 21.9% 11.8% 27.0% 34.8%
Acct.Payable 199.65
271.28
423.94
44.02
57.00
64.10
70.80
74.40
74.00
growth rate 35.9% 56.3% -89.6% 29.5% 12.5% 10.5% 5.1% -0.5%
Cur.Assets 373.50
646.60
941.27
1,495.60
2,186.86
2,796.03
2,416.00
2,578.20
2,953.90
3,385.00
5,076.40
growth rate 73.1% 45.6% 58.9% 46.2% 27.9% -13.6% 6.7% 14.6% 14.6% 50.0%
Total Assets 786.40
1,012.00
1,394.75
2,613.56
3,317.70
4,201.96
13,097.00
13,253.30
13,583.30
13,931.90
17,544.60
growth rate 28.7% 37.8% 87.4% 26.9% 26.7% 211.7% 1.2% 2.5% 2.6% 25.9%
Cash 157.20
267.10
540.87
989.50
529.86
944.00
1,010.00
966.00
584.40
1,365.50
2,685.50
growth rate 69.9% 102.5% 83.0% -46.5% 78.2% 7.0% -4.4% -39.5% 133.7% 96.7%
Inventory 40.90
62.20
81.39
94.52
102.60
176.44
290.00
374.70
460.40
472.50
627.60
growth rate 52.1% 30.9% 16.1% 8.6% 72.0% 64.4% 29.2% 22.9% 2.6% 32.8%
Cur.Liabilities 85.30
138.50
227.79
360.09
582.43
606.74
709.00
822.90
952.50
1,174.00
1,194.30
growth rate 62.4% 64.5% 58.1% 61.8% 4.2% 16.9% 16.1% 15.8% 23.3% 1.7%
Liabilities 98.00
152.30
260.26
642.71
935.62
899.94
4,838.00
4,559.50
4,690.20
4,766.60
6,272.80
growth rate 55.4% 70.9% 147.0% 45.6% -3.8% 437.6% -5.8% 2.9% 1.6% 31.6%
LT Debt 10.40
4.50
0.00
101.00
97.23
9.50
3,254.00
2,888.10
2,720.70
2,519.00
2,416.90
growth rate -56.7% -100.0% -3.7% -90.2% 34,152.6% -11.2% -5.8% -7.4% -4.1%
Equity 688.40
859.70
1,134.49
1,970.85
2,382.08
3,302.02
8,259.00
8,693.80
8,893.10
9,165.30
11,271.80
growth rate 24.9% 32.0% 73.7% 20.9% 38.6% 150.1% 5.3% 2.3% 3.1% 23.0%
Common Shares 181.00
186.00
192.00
199.00
200.00
202.00
216.00
226.00
225.00
225.00
225.00
growth rate 2.8% 3.2% 3.7% 0.5% 1.0% 6.9% 4.6% -0.4% 0.0% 0.0%
Cash Flow Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Capital Expenditures 35.30
12.80
21.98
21.85
29.33
137.00
286.30
332.70
357.30
213.00
154.70
growth rate -63.7% 71.7% -0.6% 34.3% 367.1% 109.0% 16.2% 7.4% -40.4% -27.4%
Cash Dividends 0.00 0.00 0.00 0.00
growth rate
Cash From OA 113.80
160.90
270.08
410.61
497.35
640.00
675.20
1,086.30
1,115.60
426.00
2,084.90
growth rate 41.4% 67.9% 52.0% 21.1% 28.7% 5.5% 60.9% 2.7% -61.8% 389.4%
FCF per Share 0.28
0.80
1.11
1.96
1.83
2.34
2.43
2.37
3.81
1.52
6.51
growth rate 185.7% 38.8% 76.6% -6.6% 27.9% 3.9% -2.5% 60.8% -60.1% 328.3%
Sale Purchase of Stock 35.77
517.10
5.15
114.00
82.00
37.10
85.90
growth rate 1,345.8% -99.0% 2,115.7% -28.1% -54.8% 131.5%
FCF 51.00
148.00
248.00
389.00
468.00
503.00
389.00
753.00
758.00
213.00
1,914.00
growth rate 190.2% 67.6% 56.9% 20.3% 7.5% -22.7% 93.6% 0.7% -71.9% 798.6%
Income Statement Dec '09 Dec '10 Dec '11 Dec '12 Dec '13 Dec '14 Dec '15 Dec '16 Dec '17 Dec '18 Dec '19
Sales 386.80
541.00
783.43
1,134.11
1,551.35
2,234.00
2,604.00
3,084.10
3,551.10
4,131.20
4,991.10
growth rate 39.9% 44.8% 44.8% 36.8% 44.0% 16.6% 18.4% 15.1% 16.3% 20.8%
Op.Income 87.10
150.60
175.32
254.82
252.90
916.00
682.20
793.40
983.30
1,619.90
2,139.90
growth rate 72.9% 16.4% 45.4% -0.8% 262.2% -25.5% 16.3% 23.9% 64.7% 32.1%
IBT 83.30
149.00
229.67
397.57
526.27
872.00
498.10
576.20
547.80
242.20
2,178.80
growth rate 78.9% 54.1% 73.1% 32.4% 65.7% -42.9% 15.7% -4.9% -55.8% 799.6%
Net Income 295.20
97.00
175.32
254.82
252.90
657.00
144.40
399.40
443.30
77.60
2,404.30
growth rate -67.1% 80.7% 45.4% -0.8% 159.8% -78.0% 176.6% 11.0% -82.5% 2,998.3%
EPS 1.63
0.52
0.91
1.28
1.27
3.26
0.67
1.76
1.97
0.35
10.70
growth rate -68.1% 75.0% 40.7% -0.8% 156.7% -79.5% 162.7% 11.9% -82.2% 2,957.1%
Gross Profit 341.70
476.50
690.29
1,061.28
1,373.79
2,060.00
2,370.90
2,825.80
3,249.00
3,762.70
4,596.60
growth rate 39.5% 44.9% 53.7% 29.5% 50.0% 15.1% 19.2% 15.0% 15.8% 22.2%
R&D 81.90
98.40
137.42
222.73
317.09
514.00
709.50
757.20
862.10
730.30
886.00
growth rate 20.2% 39.7% 62.1% 42.4% 62.1% 38.0% 6.7% 13.9% -15.3% 21.3%

Quarterly Statements

Item Name Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Earnings BIT 537.10
560.10
545.50
738.60
703.50
growth rate 4.3% -2.6% 35.4% -4.8%
Balance Sheet Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Acct.Receivable 1,123.60
1,116.30
1,243.20
1,345.20
1,372.20
growth rate -0.7% 11.4% 8.2% 2.0%
Acct.Payable 719.20
860.80
74.00
862.80
861.60
growth rate 19.7% -91.4% 1,066.0% -0.1%
Cur.Assets 4,168.50
4,341.20
5,076.40
4,870.20
5,367.90
growth rate 4.1% 16.9% -4.1% 10.2%
Total Assets 14,567.70
14,815.00
17,544.60
18,148.50
16,703.20
growth rate 1.7% 18.4% 3.4% -8.0%
Cash 1,984.20
2,171.30
2,685.50
2,315.00
2,825.00
growth rate 9.4% 23.7% -13.8% 22.0%
Inventory 494.60
576.70
627.60
586.80
577.70
growth rate 16.6% 8.8% -6.5% -1.6%
Cur.Liabilities 1,031.50
1,091.20
1,194.30
1,119.90
1,120.10
growth rate 5.8% 9.5% -6.2% 0.0%
Liabilities 4,404.20
4,447.80
6,272.80
6,400.70
6,212.40
growth rate 1.0% 41.0% 2.0% -2.9%
LT Debt 2,490.50
2,462.40
2,416.90
2,419.10
2,381.20
growth rate -1.1% -1.9% 0.1% -1.6%
Equity 10,163.50
10,367.20
11,271.80
11,747.80
10,490.80
growth rate 2.0% 8.7% 4.2% -10.7%
Common Shares 11,747.80
growth rate
Cash Flow Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Capital Expenditures 46.80
41.90
30.00
12.20
6.20
growth rate -10.5% -28.4% -59.3% -49.2%
Cash Dividends
growth rate
Cash From OA 538.40
599.50
517.10
549.60
790.00
growth rate 11.4% -13.7% 6.3% 43.7%
Sale Purchase of Stock
growth rate
FCF 491.60
557.60
487.10
537.40
783.80
growth rate 13.4% -12.6% 10.3% 45.9%
Income Statement Jun '19 Sep '19 Dec '19 Mar '20 Jun '20
Sales 1,203.30
1,263.10
1,384.30
1,444.80
1,444.60
growth rate 5.0% 9.6% 4.4% 0.0%
Op.Income 537.10
560.10
545.50
738.60
703.50
growth rate 4.3% -2.6% 35.4% -4.8%
IBT 499.50
535.50
602.00
663.60
-1,352.10
growth rate 7.2% 12.4% 10.2% -100.0%
Net Income 459.80
467.60
889.00
557.60
-1,068.10
growth rate 1.7% 90.1% -37.3% -100.0%
EPS
growth rate
Gross Profit 1,104.10
1,167.90
1,270.00
1,333.10
1,299.70
growth rate 5.8% 8.7% 5.0% -2.5%
R&D 187.60
232.90
269.60
200.90
221.10
growth rate 24.2% 15.8% -25.5% 10.1%

Growth Grade & Financial Ratios

All financial ratios below are calculated based on latest annual statements available and present the most up to date snapshot of a company finances.

Growth Grade

Historical Growth Grade:

A+ (93.88)

YOY Growth Grade:

C (63.88)

Click on buttons above for detailed yearly growth rates.

Market Ratios

Profitability Ratios

Liquidity Ratios

Efficiency Ratios

Value Price

PE and EPS

Historical Current Forward
PE 32.51 31.91 9.90
EPS / Growth 17.7% 3.81 12.3%

Value Price & Investment Recovery Time

Read more about Stock2Own value price in Stock Market: Fundamental Analysis.

Equity Growth Rate: 23.7%

Estimates Pessimistic Moderate Optimistic My Numbers
Rate of Return 15.0%
MOS Price % 50 %
Future EPS Growth 12.3% 17.9% 17.9%
Future PE 9.90 26.08 26.08
Future EPS 12.17 19.78 19.78
Value Price
MOS %
29.77
-75.5%
127.49
4.9%
127.49
4.9%
MOS Price 14.89 63.74 63.74
IRT 12.94 10.70 10.70

Graham Number:

NOTE: The Graham Number applies only to certain types of stocks in combination with a number of other criteria.

Read more about Graham Number in Stock Market: Fundamental Analysis.

Price Chart

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.

Risk / Reward Ratios

The functionality you are trying to reach is available to registered users only.

Login to your account or Register Now if you are not registered yet. Registration is FREE and will take only a minute.